Tragara Pharmaceuticals, Inc.

Cancer Research Today, Life Tomorrow

Learn More

About Us

Tragara is a privately held pharmaceutical company based in Carlsbad, California. The company was founded in 2007 to focus on the clinical and commercial development of proprietary medicines for the treatment of cancer. Tragara employs a lean and cost-efficient model which has the effect of minimizing overhead and focusing spending on the development programs guided by world-class key opinion leaders and advisors. The lead candidate, TG02, is currently in Phase 1b development in cancers with Myc overexpression. The core management team has successfully transitioned their years of experience developing oncology drugs in large pharmaceutical companies into the entrepreneurial biotech environment. Tragara is backed by a syndicate of premier life sciences investors, including: Domain Associates, Lee’s Pharma, Morgenthaler Ventures, ProQuest Investments, and RusnanoMedInvest.


TG02 Mechanism

TG02 potently inhibits cyclin-dependent kinase 9 leading to apoptotic effect and modulation of the cell cycle. TG02 blocks the activity of RNA polymerase II, leading to depletion of the key cancer cell survival protein, c-Myc. In glioblastoma cell lines and in vivo models, TG02 has demonstrated broad anti-tumor activity.


Overexpression of the MYC oncogene has been reported in >80% of glioblastomas. In vitro and in vivo glioma models have demonstrated that inhibition of MYC reduced proliferation and increased apoptosis.

Two TG02 clinical trials are ongoing in glioblastoma.
Link: NCT02942264
Link: NCT03224104

Hepatocellular Carcinoma

Overexpression of the MYC oncogene has been reported in 40-60% of hepatocellular tumors and is associated with poor prognosis in this patient population.

A TG02 clinical trial in hepatocellular carcinoma will initiate in 1Q 2018 in Hong Kong.

Our Team

Tracy Parrott

Acting Chief Executive Officer

Dennis Bilski

Chief Financial Officer

Thomas M. Estok

Strategic Advisor

Stuart Gallant

Head, Pharmaceutical Manufacturing

Rosemary Mazanet

Strategic Advisor

Kristan Meetze

Head, Tumor Biology

Joyce Reyes

Sr. Regulatory and Quality Representative

Board of Directors

Mauro Bove

Lee’s Pharmaceutical Holdings Inc.

Ralph E. (Chris) Christoffersen

Partner, Morgenthaler Ventures

Thomas M. Estok

President and Chief Executive Officer, Dracen Pharmaceuticals

Dennis G. Podlesak

Partner, Domain Associates

Alain Schreiber

Managing Partner, ProQuest Investments

Eckard Weber

Partner, Domain Associates

Evgeny Zaytsev

Managing Partner, RMI Partners


Tragara Pharmaceuticals, Inc.
3152 Lionshead Avenue
Carlsbad , CA 92010

Telephone: (760) 208-6900